Mabion S.A. (FRA:272)

Market Cap	29.00M -19.4%
Revenue (ttm)	4.10M -53.4%
Net Income	-13.29M
EPS	-0.82
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.740
Previous Close	1.708
Day's Range	1.740 - 1.740
52-Week Range	1.582 - 2.195
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 15, 2026

About Mabion

Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 202
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 272

Financial Performance

In 2025, Mabion's revenue was 15.76 million, a decrease of -77.17% compared to the previous year's 69.02 million. Losses were -62.61 million, 888.5% more than in 2024.

Financial numbers in PLN

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error